

## INVESTIGATION OF THE EFFICACY AND TOLERABILITY OF DR MICHAELS® (also branded as ECZITINEX® and ITCHINEX ECZITINEX®) TOPICAL PRODUCTS IN THE TREATMENT OF ATOPIC DERMATITIS IN CHILDREN

K. FRANÇA<sup>1,14</sup>, J. HERCOGOVÁ<sup>2,3</sup>, M. FIORANELLI<sup>4</sup>, S. GIANFALDONI<sup>5</sup>,  
A.A. CHOKOEVA<sup>6,7</sup>, G. TCHERNEV<sup>8</sup>, U. WOLLINA<sup>9</sup>, M. TIRANT<sup>10</sup>, P. BAYER<sup>10</sup>,  
M. COBURN<sup>10</sup>, M. SMITH<sup>10</sup>, B. DONNELLY<sup>10</sup>, T. KENNEDY<sup>10</sup>, J. GAIBOR<sup>10</sup>,  
M. ARORA<sup>10</sup>, L. CLEWS<sup>10</sup>, F. NOVOTNY<sup>11</sup>, M.G. ROCCIA<sup>12</sup>, G.K. MAXIMOV<sup>13</sup>  
and T. LOTTI<sup>15</sup>

<sup>1</sup>Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami Miller School of Medicine, Miami, FL, USA; <sup>2</sup>2nd Medical Faculty, Charles University, Bulovka Hospital, <sup>3</sup>Institute of Clinical and Experimental Medicine, Prague, Czech Republic; <sup>4</sup>Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy; <sup>5</sup>Dermatological Department University of Pisa, Pisa, Italy; <sup>6</sup>"Onkoderma"-Polyclinic for dermatology and dermatologic surgery, Sofia, Bulgaria; <sup>7</sup>Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; <sup>8</sup>Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; <sup>9</sup>Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; <sup>10</sup>Psoriasis & Skin Clinic, Melbourne, Australia; <sup>11</sup>PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic; <sup>12</sup>University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India; <sup>13</sup>Department "Medicinal Information and Non-interventional studies", Bulgarian Drug Agency, Sofia, Bulgaria; <sup>14</sup>Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy; <sup>15</sup>Chair of Dermatology, University of Rome "G. Marconi" Rome, Italy

Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10% of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.

0393-974X (2016)

Copyright © by BIOLIFE, s.a.s.

This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder.

Unauthorized reproduction may result in financial and other penalties  
DISCLOSURE: ALL AUTHORS REPORT NO CONFLICTS OF INTEREST RELEVANT TO THIS ARTICLE.